[Asia Economy Reporter Hyungsoo Park] Philosis Healthcare is showing strong performance. The news of signing a supply contract for specimen collection kits (Universal Transport Medium) with VBV appears to be influencing the stock price.
As of 9:51 AM on the 14th, Philosis Healthcare is trading at 1,780 KRW, up 29.93% compared to the previous trading day.
The specimen collection kit was jointly developed by Philosis and VBV. It received export approval from the Ministry of Food and Drug Safety on the 5th of last month.
It is compatible with the novel coronavirus (COVID-19) antigen diagnostic kit jointly developed by Philosis and VBV. It is also included and sold together with the COVID-19 diagnostic kit (Gmate COVID-19) marketed by Philosis Healthcare.
VBV, a specialized diagnostic kit company, is actively collaborating with various companies. It has jointly developed hospital-use blood glucose meters and plasma separation technology with Philosis, and recently signed a joint development contract for a COVID-19 antigen diagnostic kit with Celltrion.
The Gmate Check and Gmate True-plasma, which apply this technology, currently contribute significantly to Philosis's sales. The COVID-19 antigen diagnostic kit developed with Celltrion is also nearing release.
Philosis Healthcare, which owns the distribution rights for the specimen collection kit, is reportedly in the process of a supply contract for the specimen collection kit in the United States. Negotiations are underway with Premier, a U.S. Group Purchasing Organization (GPO), and the largest medical device distributor in the U.S. regarding supply timing and quantity. The supply quantity is expected to be about 1 million units. The FDA approval process with a medical device distribution company in Miami is also in its final stages. Once FDA approval is obtained, the plan is to supply to the U.S. government and hospitals.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
